SG11201909932YA - Pharmaceutical agents, compositions, and methods relating thereto - Google Patents
Pharmaceutical agents, compositions, and methods relating theretoInfo
- Publication number
- SG11201909932YA SG11201909932YA SG11201909932YA SG11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nicholasville
- catnip
- hill road
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508730P | 2017-05-19 | 2017-05-19 | |
| PCT/US2018/030371 WO2018212980A1 (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909932YA true SG11201909932YA (en) | 2019-11-28 |
Family
ID=64274560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909932Y SG11201909932YA (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11014954B2 (enExample) |
| EP (1) | EP3624809A4 (enExample) |
| JP (1) | JP7224303B2 (enExample) |
| CN (2) | CN120647702A (enExample) |
| AU (1) | AU2018269403B2 (enExample) |
| CA (1) | CA3061893A1 (enExample) |
| RU (1) | RU2765286C2 (enExample) |
| SA (1) | SA519410561B1 (enExample) |
| SG (1) | SG11201909932YA (enExample) |
| WO (1) | WO2018212980A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002305073A1 (en) * | 2001-03-22 | 2002-10-08 | Research Foundation Of The City University Of New York | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| EP1652519A1 (en) | 2004-10-28 | 2006-05-03 | Tamie Nasu | Seleniferous composition for producing antioxidase in vivo |
| US20060198906A1 (en) | 2005-03-07 | 2006-09-07 | Sami Labs Limited | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease |
| US20070077238A1 (en) | 2005-10-04 | 2007-04-05 | Teo Alex Y | Production of organic and inorganic selenium compounds by lactic acid bacteria |
| US7488720B2 (en) * | 2005-10-13 | 2009-02-10 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| EP2192905A4 (en) | 2007-08-29 | 2010-11-10 | Adam Lubin | METHOD FOR SELECTIVE THERAPY OF DISEASE |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| CN105377271A (zh) | 2013-03-15 | 2016-03-02 | 全技术公司 | 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 |
| MX2016011897A (es) * | 2014-03-14 | 2017-04-27 | Alltech Inc | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. |
| US20160090397A1 (en) | 2014-09-30 | 2016-03-31 | Northeastern University | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
-
2018
- 2018-05-01 CN CN202510741418.6A patent/CN120647702A/zh active Pending
- 2018-05-01 CA CA3061893A patent/CA3061893A1/en active Pending
- 2018-05-01 US US16/490,836 patent/US11014954B2/en active Active
- 2018-05-01 JP JP2019563067A patent/JP7224303B2/ja active Active
- 2018-05-01 SG SG11201909932Y patent/SG11201909932YA/en unknown
- 2018-05-01 EP EP18801931.9A patent/EP3624809A4/en active Pending
- 2018-05-01 AU AU2018269403A patent/AU2018269403B2/en active Active
- 2018-05-01 CN CN201880027339.7A patent/CN110545822A/zh active Pending
- 2018-05-01 WO PCT/US2018/030371 patent/WO2018212980A1/en not_active Ceased
- 2018-05-01 RU RU2019134865A patent/RU2765286C2/ru active
-
2019
- 2019-11-14 SA SA519410561A patent/SA519410561B1/ar unknown
-
2021
- 2021-04-23 US US17/238,354 patent/US11613552B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2765286C2 (ru) | 2022-01-28 |
| NZ758538A (en) | 2025-08-29 |
| JP7224303B2 (ja) | 2023-02-17 |
| WO2018212980A1 (en) | 2018-11-22 |
| CN110545822A (zh) | 2019-12-06 |
| EP3624809A1 (en) | 2020-03-25 |
| US11613552B2 (en) | 2023-03-28 |
| BR112019022918A2 (pt) | 2020-05-26 |
| CN120647702A (zh) | 2025-09-16 |
| RU2019134865A (ru) | 2021-06-21 |
| RU2019134865A3 (enExample) | 2021-06-30 |
| AU2018269403B2 (en) | 2025-03-27 |
| EP3624809A4 (en) | 2021-03-03 |
| US11014954B2 (en) | 2021-05-25 |
| JP2020520904A (ja) | 2020-07-16 |
| SA519410561B1 (ar) | 2024-03-06 |
| US20210238216A1 (en) | 2021-08-05 |
| US20200123191A1 (en) | 2020-04-23 |
| CA3061893A1 (en) | 2018-11-22 |
| AU2018269403A1 (en) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201908472VA (en) | Compositions and methods for activating nk cells | |
| SG11201908490TA (en) | Compositions and methods and uses relating thereto |